Alluvi, known as BI 4744, presents a significant advance in obesity care. This dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide sites demonstrates remarkable results in patient https://alluvihealthcare981050.wikicommunication.com/user